IMMUNE THROMBOCYTOPENIA
Clinical trials for IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for ITP patients: antibody drug takes on standard therapy
Disease control Recruiting nowThis study compares a new drug called daratumumab with the standard drug rituximab in 160 adults with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. The goal is to see which drug works better at raising platelet counts and redu…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 09:38 UTC
-
New hope for patients with low platelets? early trial launches
Disease control Recruiting nowThis early study tests a new drug called PRG-1801 in 6 adults with immune thrombocytopenia (ITP) that hasn't improved with standard treatments. The goal is to see if the drug is safe and can raise platelet counts to reduce bleeding risk. Participants receive a single infusion and…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 26, 2026 09:34 UTC
-
New pill shows promise for rare bleeding disorder
Disease control Recruiting nowThis study tests an oral drug called rilzabrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants must have failed first-line treatment. The goal is to see if the drug can safely raise platelet …
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated May 26, 2026 09:33 UTC
-
New drug offers hope for rare blood disorders
Disease control Recruiting nowThis study tests a drug called tafasitamab in adults with two autoimmune blood disorders: immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The goal is to see if the drug can safely raise low blood cell counts and reduce symptoms. About 56 participants w…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 09:32 UTC
-
New injection aims to control rare bleeding disorder
Disease control Recruiting nowThis early-stage study tests a new drug called SHR-2173 in 10 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The main goal is to see if the drug is safe and tolerable. Researchers will also check if it helps ra…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 26, 2026 09:31 UTC
-
New drug cocktail aims to rescue ITP patients who failed steroids
Disease control Recruiting nowThis study tests whether combining two drugs (rituximab and daratumumab) can safely raise platelet counts in adults with immune thrombocytopenia (ITP) who did not get better with steroids. About 20 participants will receive the combo and be monitored for 12 weeks. The goal is to …
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 09:29 UTC
-
New hope for kids with Hard-to-Treat ITP: daratumumab takes on rituximab
Disease control Recruiting nowThis study compares two medications, daratumumab and rituximab, in children aged 6 to 17 with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to see w…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for ITP patients: drug combo aims to boost platelets
Disease control Recruiting nowThis study tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with immune thrombocytopenia (ITP) who did not improve or relapsed after steroid treatment. The goal is to safely raise platelet counts and reduce ble…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New hope for kids with Hard-to-Treat bleeding disorder
Disease control Recruiting nowThis study tests a new drug (anti-CD38 antibody) in 60 children aged 6 and older with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The drug aims to raise platelet counts safely in kids who haven't improved with standard …
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New study tests if antibody blood test can spot autoimmune platelet disorder
Knowledge-focused Recruiting nowThis study is testing whether a special blood test (MAIPA) can help doctors tell if a low platelet count is caused by an autoimmune problem. It will include 225 adults with low platelets who haven't started treatment yet. The goal is to see if the test can make diagnosis faster a…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated May 26, 2026 09:31 UTC
-
New french registry aims to uncover real-world patterns in rare blood diseases
Knowledge-focused Recruiting nowThis study is a national registry in France that collects information on adults newly diagnosed with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). Researchers will track up to 1,500 patients to describe how these diseases progress, how they are treated in r…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC